Skip to content

Multimodal Imaging Evaluation of Intravitreal Sustained-Release Implant for Noninfectious Uveitis: A Bidirectional Cohort Study

Multimodal Imaging Evaluation of Intravitreal Sustained-Release Implant for Noninfectious Uveitis: A Bidirectional Cohort Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600128651
Enrollment
Unknown
Registered
2026-07-23
Start date
2026-07-25
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Uveitis

Interventions

Fluocinolone acetonide intravitreal implant group:0.18 mg fluocinolone sustained-release implant
Dexamethasone intravitreal implant group:0.7 mg dexamethasone implant

Sponsors

General Hospital of Central Theater Command, People's Liberation Army (PLA)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age >= 18 years; 2. Clinically diagnosed with non-infectious uveitis involving the posterior segment, in accordance with the standards of the Standardisation of Uveitis Nomenclature (SUN) Working Group, with posterior segment involvement confirmed by fundus examination, fluorescein angiography (FFA) and optical coherence tomography (OCT), whilst infectious aetiologies have been ruled out; 3. Treated with FAi (single implantation) or DEX (repeated injections as required); 4. Had not previously received intravitreal corticosteroid implants prior to this indicated treatment; 5. Follow-up duration of >=12 months, with complete data on best-corrected visual acuity (BCVA), intraocular pressure (IOP), central macular thickness (CMT) and subfoveal choroidal thickness (SFCT) at baseline and at months 1, 3, 6 and 12.

Exclusion criteria

Exclusion criteria: 1. Infectious uveitis, including fungal, tuberculous or syphilitic uveitis; 2. Baseline intraocular pressure > 21 mmHg, a history of glaucoma, or evidence of glaucomatous optic neuropathy; 3. Significant opacities in the optical media that prevent adequate fundus imaging; 4. Incomplete follow-up data.

Design outcomes

Primary

MeasureTime frame
12-month recurrence rate of uveitis;Time to first recurrence;

Secondary

MeasureTime frame
best-corrected visual acuity ;central macular thickness;Number and interval of re-treatments;Proportion of patients with systemic corticosteroids / immunomodulatory therapy;Inflammation control rate;

Countries

CHINA

Contacts

Public ContactZhang Wenjing

General Hospital of Central Theater Command, PLA

zhangwenjingdhs@126.com+86 173 2182 1987

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Aug 10, 2026